Seegene Inc, a South Korea-based developer of molecular diagnostics (MDx) solutions, announced on Tuesday the launch of STAgora, a next-generation platform for infectious disease analytics.
Designed as a real-time infectious disease intelligence system, the company says that the platform combines diagnostic data with advanced statistical modelling and aims to redefine how the world detects, tracks and responds to outbreaks.
STAgora provides real-time global visualisation of infectious disease trends at the municipal, national and continental levels, based on actual diagnostic test results. It also delivers healthcare professionals immediate, structured diagnostic reports and statistical analyses in clear, actionable formats. These are supported by customisable dashboards and real-time alert functions.
In addition to tracking individual cases, STAgora enables users to monitor outbreaks across selected regions, both local and international. This capability is designed to provide real-time visibility into disease spread, enhancing situational awareness and supporting timely, data-driven public health responses. By equipping national and global health authorities with real-time epidemiological insight, the platform is expected to strengthen decision-making and support the development of effective response strategies to mitigate large-scale infectious disease outbreaks.
Seegene says that it will officially debut STAgora at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting, taking place from 27 to 31 July in Chicago, USA. The event will highlight key capabilities of the platform, including its integration with CURECA, Seegene's fully automated, unmanned PCR system. ADLM 2025 will also serve as a launchpad for Seegene to explore global collaboration and partnerships with healthcare leaders and clients.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne